Navigation Links
Experimental Drug Shows Promise Against Type 2 Diabetes
Date:2/27/2012

SUNDAY, Feb. 26 (HealthDay News) -- An experimental drug improves patients' blood sugar control without increasing the risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, according to the results of a phase 2 clinical trial.

Type 2 diabetes is the more prevalent form of the disease, accounting for about 90 percent of cases. Often tied to obesity, type 2 diabetes involves a gradual decline in how insulin responds to changes in blood sugar (glucose).

The new drug, called TAK-875, is a pill designed to enhance the secretion of insulin in response to such changes, which means that it has no effect on insulin secretion when blood sugar levels are normal -- potentially reducing the risk for hypoglycemia.

The trial, led by Dr. Charles Burant of the University of Michigan Medical School, included 426 patients with type 2 diabetes who were not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.

The patients were randomly assigned to receive either TAK-875 (303 patients), placebo (61 patients), or another diabetes drug called glimepiride (brand named Amaryl).

The study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.

After 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said. A similar reduction occurred in patients taking glimepiride.

However, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).

The incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers. They write that they are "excited about the potential of TAK-875 and are eager to conduct larger trials to find out how well this drug works, how safe it is and what its place is in the treatment of diabetes."

In a journal commentary, Clifford Bailey of Aston University in Birmingham, England, cautioned that, "on the journey to approval of a new class of treatment for type 2 diabetes, many questions will be asked of [drugs such as TAK-875]," including questions of how long they might remain effective, as well as safety issues.

Other diabetes experts had mixed views on the new findings.

Dr. Loren Wissner Greene is clinical associate professor of endocrinology at NYU Langone Medical Center in New York City. She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (Avandia was recently withdrawn from the U.S. market due to heart risks).

As for TAK-875, it targets a separate mechanism "but again, until more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism," Wissner Greene said.

Dr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, "given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents."

She said that, "though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain. However, like Wissner-Greene, Sood said that "further investigation is warranted, especially including [heart disease] patients."

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.

-- Robert Preidt

SOURCE: Loren Wissner Greene, MD, clinical associate professor, endocrinology, NYU Langone Medical Center, New York City; Minisha Sood, MD, endocrinologist, Lenox Hill Hospital, New York City ; The Lancet, news release, Feb. 24, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. First-in-human drug for malignant glioma available in experimental trial
2. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
3. Experimental Drugs Do Battle Against Advanced Prostate Cancer
4. Experimental Blood Thinner Given Before Surgery Shows Benefit
5. Wolfson Foundation awards £20 million to UCL for experimental neurology center
6. Novel experimental agent is highly active in CLL patients, interim study shows
7. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
8. Experimental Drug Slims Obese Monkeys
9. Experimental Psoriasis Drug Bests Older Treatment
10. Experimental Vaccine Shows Promise for Lung Cancer: Study
11. Experimental vaccine protects monkeys from blinding trachoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Shows Promise Against Type 2 Diabetes
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology: